Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Syndax Pharmaceuticals Inc (SNDX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/03/2023 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update – Announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in cGVHD – – Topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia on track for the third quarter of 2023 – – Two U.S. registrational filings expected by the end of 2023 – – Company to host conference call today at 4:30 p.m. ET –"
07/24/2023 8-K Quarterly results
05/26/2023 8-K Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive ...
Docs: "SYNDAX PHARMACEUTICALS, INC. common Stock SALES AGREEMENT",
"Building D, Floor 3"
05/08/2023 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update – Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD on track for mid-2023 – – Topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia on track for the third quarter of 2023 – – Two U.S. registrational filings expected by the end of 2023 – – Company to host conference call today at 4:30 p.m. ET –"
03/30/2023 8-K Quarterly results
02/28/2023 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update – Topline data from AUGMENT-101 KMT2Ar patients expected in the third quarter of 2023 – – Topline data from the pivotal AGAVE-201 trial on track for mid-2023 – – Two U.S. registrational filings expected by the end of 2023 – – Company to host conference call today at 4:30 p.m. ET –"
02/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SYNDAX PHARMACEUTICALS, INC. 2023 INDUCEMENT PLAN Syndax Pharmaceuticals, Inc., a Delaware corporation , sets forth herein the terms of its 2023 Inducement Plan , as follows: 1. GENERAL 1.1 Purpose. This Plan is intended to provide an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635 of the NASDAQ Marketplace Rules, and incentives to Eligible Employees to stimulate their efforts towards the success of the Company and to operate and manage its business in a manner that will provide for the long-term growth and profitability of the Company. To that end, the Plan provides for the grant of Awards of Options, Stock Appreciation Rights, Restricted Stock, Unrestricted Stock, Stock Units, Dividend Equivalent Rights, Performance Aw...",
"Non-qualified Option This Agreement evidences an award of an Option exercisable for that number of shares of Stock set forth on the cover sheet and subject to the vesting and other conditions set forth in the Agreement and in the Plan. This Option is granted subject to the terms and conditions of the Plan as a material inducement to you entering into employment with the Company in compliance with NASDAQ Listing Rule 5634. This Option is not intended to be an incentive stock option under Section 422 of the Code and will be interpreted accordingly. Transfer of Option During your lifetime, only you may exercise the Option. The Option may not be sold, assigned, transferred, pledged, hypothecated or otherwise encumbered, whether by operation of law or otherwise, nor may the Option be made subje..."
12/14/2022 8-K Quarterly results
12/07/2022 8-K Quarterly results
12/05/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
09/23/2022 8-K Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  ...
08/08/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update - Enrollment remains on track for pivotal programs of SNDX-5613 and axatilimab; topline data expected starting in the first half of 2023 -",
"Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer"
02/24/2022 8-K Quarterly results
02/03/2022 8-K Quarterly results
12/23/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
12/17/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among the Company and Goldman Sachs & Co. LLC",
"Form of Pre-Funded Warrant (2021)",
"Opinion of Cooley LLP"
12/13/2021 8-K Quarterly results
12/09/2021 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update – Initiated pivotal Phase 2 portion of SNDX-5613 AUGMENT-101 trial in patients with NPM1 and MLLr acute leukemias –"
10/04/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/27/2021 8-K Quarterly results
09/15/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
02/05/2021 8-K Quarterly results
12/09/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and among the Company, Goldman Sachs & Co. LLC, Citigroup Global Markets Inc. and Cowen and Company, LLC",
"Opinion of Cooley LLP"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy